Klotho Neurosciences, Inc. Material Event - Investor Summary

Klotho Neurosciences, Inc. (KLTO) has just announced a seismic shift that will fundamentally redefine the company. Once a biotech pure-play, Klotho has acquired a mining giant, completely transforming its business model and strategic direction. This summary provides retail investors with a clear, concise overview of this groundbreaking event, highlighting key details, financial implications, and future considerations.

1. Event Description (The Core Announcement: A Biotech Company Acquires a Mining Giant)

On March 4, 2026, Klotho Neurosciences, previously a company focused solely on neuroscience drug development, announced its acquisition of Greenland Mines Corp. The companies signed the merger agreement on March 3, 2026, and closed the deal the very next day.

This acquisition represents more than just an expansion; it's a strategic pivot. Greenland Mines Corp. holds an 80% interest (with an option for the remaining stake) in the Skaergaard Project in Southeast Greenland. This project stands as one of the world's largest undeveloped deposits of palladium, gold, platinum, and other critical minerals, boasting an estimated $68 billion value of minerals in the ground.

To reflect this dramatic shift, Klotho Neurosciences plans to rebrand and change its stock ticker to "Greenland Mines" in late March 2026.

Strategic Rationale: Klotho's CEO, Dr. Joseph Sinkule, articulated several reasons for this unexpected pivot:

• Strategic Diversification: The company aims to create a "uniquely diversified company" by pairing a "world-class mineral asset with our existing biotech platform."
• Securing Critical Minerals: The company positions the Skaergaard Project as a "western champion in critical mineral supply security."
• Unlocking Massive Asset Value: The estimated $68 billion "in the ground" value represents a substantial long-term asset.

New Company Structure: The company will now operate under two strategic divisions:

1. Natural Resources: Focused on the development and operation of the Skaergaard Project in Greenland.
2. Cell and Gene Therapy: Klotho's original biotech business, including its KLTO-202 treatment for ALS, which the company confirms will continue.

Klotho's existing CEO and CFO will remain, while Greenland Mines' leadership team will join to manage the new Natural Resources division.

2. Event Date/Timeline

• March 3, 2026: Merger agreement signed.
• March 4, 2026: Acquisition announced and closed.
• Late March 2026: Expected rebranding and stock ticker change to "Greenland Mines".
• Ongoing: Further investor communications, operational roadmap development, and governance details are anticipated.

3. Impact Assessment (Who/What is Affected)

This acquisition fundamentally alters Klotho Neurosciences' business model, strategic direction, and risk profile, affecting various stakeholders:

• Shareholders: Existing Klotho shareholders will experience significant dilution, owning approximately 7% of the combined entity post-acquisition. Their investment thesis shifts from a pure-play biotech company to a diversified entity with a primary focus on mining.
• Company Strategy & Operations: The company transitions from a singular biotech focus to operating two distinct and highly disparate divisions: cutting-edge biotech and large-scale mining. This introduces significant operational complexity.
• Management: Klotho's existing CEO and CFO will remain, with Greenland Mines' leadership joining to manage the new Natural Resources division, indicating a blended management approach.
• Risk Profile: The company's risk profile dramatically changes, incorporating risks associated with capital-intensive mining projects, commodity price volatility, geopolitical factors, and environmental regulations, in addition to existing biotech risks.
• Valuation: Valuing a combined biotech and mining entity can be complex for analysts and investors, potentially leading to market uncertainty.

4. Financial Impact

Klotho Neurosciences structured this transaction as a reverse merger for accounting purposes. It paid for Greenland Mines Corp. entirely with convertible preferred stock.

Crucially for existing Klotho shareholders: On an "as-converted" basis, Greenland Mines Corp. shareholders will own approximately 93% of Klotho's fully diluted shares outstanding after the acquisition. This means existing Klotho shareholders face significant dilution, owning a much smaller percentage of the combined entity. The implied valuation of Greenland Mines Corp. in this transaction significantly exceeds Klotho's pre-merger valuation.

While we know about the significant dilution, the company didn't provide all the nitty-gritty details yet, like the exact dollar value of the convertible preferred stock issued, the number of shares, or the specific terms of that preferred stock (things like conversion ratios, dividend rights, or liquidation preferences). These details are usually found in a full 8-K filing, along with pro forma financial information, which we'll need to wait for.

The Skaergaard Project's estimated $68 billion value of minerals in the ground represents a substantial long-term asset, though realizing this value requires significant capital expenditure and has a long development timeline. The company has not yet disclosed the estimated capital required or its financing plan for these stages.

5. Key Takeaways for Investors

This is an unprecedented and significant event for Klotho Neurosciences. Investors must re-evaluate their investment thesis based on this new, highly diversified, and capital-intensive business model.

Key Risks and Considerations:

• Extreme Dilution: Existing Klotho investors will have a significantly reduced stake.
• Industry Shift: Investors who bought Klotho for its biotech potential are now invested in a company primarily focused on mining, an industry with vastly different dynamics, risks, and valuation metrics.
• Operational Complexity: Managing two highly disparate businesses presents significant operational and management challenges.
• Capital Requirements & Future Financing: The mining division will likely require substantial capital, potentially leading to further equity dilution or debt financing.
• Commodity Price Volatility: Profitability of the mining division will be subject to volatile global prices.
• Geopolitical & Regulatory Risks: Mining operations are exposed to geopolitical instability, trade policies, and evolving environmental regulations.
• Valuation Challenge: Valuing a combined biotech and mining entity can be complex.
• Commitment to Biotech: While the company states the biotech division will continue, the relative focus and investment in neuroscience research may shift.

What Happens Next?

• Rebranding: The company expects to change its name and stock ticker to "Greenland Mines" in late March 2026.
• Investor Communications: Expect further investor calls and presentations detailing the strategic vision, operational plans, and financial projections.
• Operational Roadmap: Investors should look for concrete timelines and milestones for the Skaergaard Project's development.
• Governance: Details on the board composition and overall control structure of the new entity will be important.